-
Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as its new Chief Medical Officer (CMO). In this role, Dr. Koneru will be responsible for leading the company’s clinical development and medical affairs programs, further strengthening Legend’s executive team. Dr. Koneru’s Background and ExperienceDr. Koneru…
-
Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA
•
China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its biosimilar version of Roche’s Avastin (bevacizumab) has been accepted for review by Brazil’s National Health Surveillance Agency (ANVISA). Luye’s Biosimilar Approval and Global OutlookLuye’s biosimilar bevacizumab was approved in China in 2021 to treat indications…
-
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
•
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have been released, detailing the volumes and provinces awarded for each tender. The round saw RMB 3.775 billion (USD 550 million) in bid spots distributed among a total of 152 manufacturers, resulting in over 252 valid…
-
Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment
•
Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China of Zeposia (ozanimod), the world’s first selective sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of recurrent multiple sclerosis (MS). This includes clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis. Mode…
-
Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers
•
The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation of the inter-provincial volume-based procurement (VBP) tender results for pacemakers. This move requires affected manufacturers to complete the necessary steps for winning bids maintenance and filing. Additionally, relevant manufacturing delivery companies and medical institutions are…
-
Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from the US FDA for its investigational drug ZG006, intended to treat small-cell lung cancer and other solid tumors. ZG006: A Tri-Specific Antibody Targeting CD3 and DLL3 EpitopesZG006 is a tri-specific antibody developed through the company’s…
-
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
•
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National Medical Products Administration (NMPA) for its product Carteyva (relmacabtagene autoleucel injection; relma-cel). The treatment will be assessed for its efficacy in managing moderate-to-severe refractory systemic lupus erythematosus (SLE). Understanding Systemic Lupus Erythematosus (SLE)SLE is a…
